Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis

Guillaume Butler-Laporte, Elizabeth Smyth, Alexandre Amar-Zifkin, Matthew P Cheng, Emily G McDonald, Todd C Lee, Guillaume Butler-Laporte, Elizabeth Smyth, Alexandre Amar-Zifkin, Matthew P Cheng, Emily G McDonald, Todd C Lee

Abstract

Background: Pneumocystis jirovecii pneumonia (PJP) remains a common and highly morbid infection for immunocompromised patients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the antimicrobial treatment of choice. However, treatment with TMP-SMX can lead to significant dose-dependent renal and hematologic adverse events. Although TMP-SMX is conventionally dosed at 15-20 mg/kg/d of trimethoprim for the treatment of PJP, reduced doses may be effective and carry an improved safety profile.

Methods: We conducted a systematic search in the Medline, Embase, and Cochrane Library databases from inception through March 2019 for peer-reviewed studies reporting on reduced doses of TMP-SMX (15 mg/kg/d of trimethoprim or less) for the treatment of PJP. PRISMA, MOOSE, and Cochrane guidelines were followed. Gray literature was excluded.

Results: Ten studies were identified, and 6 were included in the meta-analysis. When comparing standard doses with reduced doses of TMP-SMX, there was no statistically significant difference in mortality (absolute risk difference, -9% in favor of reduced dose; 95% confidence interval [CI], -27% to 8%). When compared with standard doses, reduced doses of TMP-SMX were associated with an 18% (95% CI, -31% to -5%) absolute risk reduction of grade ≥3 adverse events.

Conclusions: In this systematic review, treatment of PJP with doses of ≤10 mg/kg/d of trimethoprim was associated with similar rates of mortality when compared with standard doses and with significantly fewer treatment-emergent severe adverse events. Although limited by the observational nature of the studies included, this review provides the most current available evidence for the optimal dosing of TMP-SMX in the treatment of PJP.

Keywords: HIV; Pneumocystis jirovecii; TMP-SMX; transplantation.

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Prisma flow diagram. Abbreviations: RCT, randomized controlled trial; TMP-SMX, trimethoprim-sulfamethoxazole.
Figure 2.
Figure 2.
Standard-dose vs reduced-dose trimethoprim-sulfamethoxazole mortality meta-analysis. Results are reported as relative risk difference. Abbreviations: CI, confidence interval; RD, risk difference.
Figure 3.
Figure 3.
Standard-dose vs reduced-dose trimethoprim-sulfamethoxazole adverse events meta-analysis. Results are reported as relative risk difference. Abbreviations: CI, confidence interval; RD, risk difference.
Figure 4.
Figure 4.
Reduced-dose mortality Pneumocystis carinii pneumonia mortality rates with reduced doses of trimethoprim-sulfamethoxazole, including single-arm cohorts with HIV patients. Results are reported in relative risk. Abbreviation: CI, confidence interval.
Figure 5.
Figure 5.
Mortality rate from historical control cohort of standard dose trimethoprim-sulfamethoxazole, as extracted from eligible randomized controlled trials on Pneumocystis carinii pneumonia therapy. Abbreviation: CI, confidence interval.

References

    1. Roux A, Canet E, Valade S, et al. . Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20:1490–7.
    1. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118:704–11.
    1. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42:780–9.
    1. Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 1975; 112:47–50.
    1. Medina I, Mills J, Leoung G, et al. . Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776–82.
    1. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011; 183:1851–8.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
    1. Stroup DF, Berlin JA, Morton SC, et al. . Meta-analysis Of Observational Studies in Epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008–12.
    1. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. United Kingdom: The Cochrane Collaboration; 2011. Available at: .
    1. Sterne JA, Hernán MA, Reeves BC, et al. . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355:i4919.
    1. Kosaka M, Ushiki A, Ikuyama Y, et al. . A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without HIV infection. Antimicrob Agents Chemother 2017; 61: e01173–7.
    1. Nakashima K, Aoshima M, Nakashita T, et al. . Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect 2018; 51:810–20.
    1. Ohmura SI, Naniwa T, Tamechika SY, et al. . Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study. J Infect Chemother 2019; 25:253–61.
    1. Schmidt JJ, Lueck C, Ziesing S, et al. . Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care 2018; 22:307.
    1. Lee KY, Huang CH, Tang HJ, et al. . Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study. J Antimicrob Chemother 2012; 67:2749–54.
    1. National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events. 2019 Available at:. Accessed 11 January 2020.
    1. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109:280–7.
    1. Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis 2009; 41:862–8.
    1. Yang JJ, Huang CH, Liu CE, et al. . Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One 2014; 9:e106141.
    1. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323(21):1444–50.
    1. Klein NC, Duncanson FP, Lenox TH, et al. . Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992; 6:301–5.
    1. Safrin S, Finkelstein DM, Feinberg J, et al. . Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124:792–802.
    1. Sattler FR, Frame P, Davis R, et al. . Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis 1994; 170:165–72.
    1. Toma E, Fournier S, Dumont M, et al. . Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis 1993; 17:178–84.
    1. Toma E, Thorne A, Singer J, et al. . Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis 1998; 27:524–30.
    1. Wharton JM, Coleman DL, Wofsy CB, et al. . Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105:37–44.
    1. Creemers-Schild D, Kroon FP, Kuijper EJ, de Boer MG. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection 2016; 44:291–9.
    1. Eeftinck Schattenkerk JK, Lange JM, van Steenwijk RP, Danner SA. Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity. J Intern Med 1990; 227:359–62.
    1. Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget 2017; 8:59729–39.
    1. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140:1204–9.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다